Integrated Multiomics Validation of Key MUC Gene Expression for the Signature Biomarker in the Pakistani Cohort
BioMed Research International · 2025
DOI: 10.1155/bmri/9777346 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, 2025. Verfasst von Maryam Naeem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Quaid-e-Azam University, Islamabad, Pakistan, qau.edu.pk. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Purpose
Pancreatic ductal adenocarcinoma (PDAC) is the 3 rd leading cause of cancer‐related mortalities and has a poor prognosis, with a 5‐year survival of 8%–9%. The major challenge associated with management of PDAC is delayed diagnosis. Diagnosis at an early stage can significantly increase the survival. Therefore, we used multiomics analysis to validate a novel signature biomarker of early‐stage PDAC. The signature was derived from a computational analysis and subsequently validated in the Pakistani patient cohort, including patients with well‐defined early‐stage (I and II) PDAC.
Methods
With the aim of validating the signature biomarker ( MUC3A / MUC4 / MUC13 / MUC16 ) as a potent early diagnostic and prognostic marker, a comprehensive analysis of multiomics data of the Pakistani cohort was performed utilizing the integrated whole‐exome sequencing, transcriptome analysis, and RT‐qPCR.
Results
The in vitro validation of a signature biomarker in the Pakistani cohort reveals the pathogenic effect of mutations in the key MUC genes and its profound effect on its protein functionality. Among all key MUC genes analyzed in a transcriptomic dataset, only MUC4 exhibits statistically significant differential expression. Finally, RT‐qPCR results demonstrate significant overexpression of all key MUC genes in PDAC blood samples.
Conclusion
In conclusion, our findings suggest MUC3A/MUC4/MUC13/MUC16 as robust diagnostic and prognostic biomarkers and liquid biopsy as a noninvasive approach to be integrated into daily clinical practice. This analysis can also be extended to other malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Department, Quaid-e-Azam University, Islamabad, Pakistan, qau.edu.pk.
- Alpha Genomics Private Limited, Islamabad, Pakistan.
- Microbiological Analysis Team, Group for Biometrology, Korea Research Institute of Standards and Science (KRISS), Daejeon, Republic of Korea, kriss.re.kr.
ORCID-Profile: Maryam Naeem, Nimra Munir, Ibrar Ahmed, Zarrin Basharat, Aneesa Sultan
Förderung
- National Research Foundation of Korea
Zitieren
APA
Naeem, M., Munir, N., Ahmed, I., Basharat, Z., & Sultan, A. (2025). Integrated Multiomics Validation of Key MUC Gene Expression for the Signature Biomarker in the Pakistani Cohort. BioMed Research International. https://doi.org/10.1155/bmri/9777346
Vancouver
Naeem M, Munir N, Ahmed I, Basharat Z, Sultan A. Integrated Multiomics Validation of Key MUC Gene Expression for the Signature Biomarker in the Pakistani Cohort. BioMed Research International. 2025. doi:10.1155/bmri/9777346
BibTeX
@article{Naeem2025,
author = {Naeem, Maryam and Munir, Nimra and Ahmed, Ibrar and Basharat, Zarrin and Sultan, Aneesa},
title = {Integrated Multiomics Validation of Key MUC Gene Expression for the Signature Biomarker in the Pakistani Cohort},
journal = {BioMed Research International},
year = {2025},
doi = {10.1155/bmri/9777346}
}
EUVIMED